CDERLearn Training and Education
Learning opportunities for healthcare professionals, industry, consumers, and academia
Upcoming Free CE Opportunities
For Health Care Professionals
For Industry
| Summary | Type | Topic |
|---|---|---|
| Biosimilars Level 1: Foundational Concepts | Health Care Professional | Biosimilars |
| Biosimilars Level 2: Regulatory and Scientific Concepts | Health Care Professional | Biosimilars; Drug Regulatory Process |
| Biosimilars Videos | Healthcare Professional; Videos | Biosimilars; Drug Regulatory Process |
| Drug Approval Case Studies | Health Care Professional; Industry | Drug Regulatory Process |
| FDA’s Role in Public Health: Drug Efficacy, Safety, Quality, and Beyond | Health Care Professional; CE Eligible | Drug Regulatory Process |
| Practitioners’ Guide for Improving Oral Anticoagulant Use | Health Care Professional; CE Eligible | Oral Anticoagulant; Disease States |
| The FDA Bad Ad Program and Prescription Drug Promotion | Health Care Professional; CE Eligible | Prescription Drug Promotion |
| FDA MedWatch and Patient Safety | Health Care Professional | MedWatch; Drug Safety |
| The FDA Process for Approving Generic Drugs | Health Care Professional; Industry | Drug Regulatory Process; Drug Development; Generic Drugs |
| FDA Overview of Biosimilar Products | Health Care Professional; Industry | Biosimilars |
| Leveraging Health Literacy and Patient Preferences to Reduce Hypoglycemia Events in Patients with Type 2 Diabetes | Health Care Professional | Diabetes; Disease States |
| Electronic Common Technical Document (eCTD) | Industry | Electronic Submissions |
| Best Practices for Communication Between FDA and IND Sponsors During Drug Development | Industry | Drug Development; IND |
| Overview of the Generic Drug User Fee Amendments of 2012 (GDUFA) | Industry | Drug Development; Generic Drugs |
| GDUFA Self-Identification (SPL) Submission – Part 1 | Industry | Drug Development; Generic Drugs |
| GDUFA Self-Identification (SPL) Submission – Part 2 | Industry | Drug Development; Generic Drugs |
| Bringing an Over-the-Counter (OTC) Drug to Market | Industry | Drug Development; OTC Drug Regulations |
| Chemistry, Manufacturing, and Controls (CMC) Perspective of the IND | Industry | Drug Development; IND |
| Engaging with the FDA During New Drug Development | Industry | Drug Development |
| Human Drug Establishment Registration and Drug Listing Compliance | Industry | Registration and Listing |
| Director's Corner Podcasts | Industry; Podcasts | Drug Regulatory Process; Drug Development |
| Drug Information Soundcast in Clinical Oncology (D.I.S.C.O) | Health Care Professional; Industry; Podcasts | Cancer Drugs |
| FDA Drug Safety Podcasts | Health Care Professional; Industry; Podcasts | Drug Safety |
| Regulatory Science at CDER Podcasts | Industry; Podcasts | Drug Development |
| Small Business and Industry Assistance (SBIA) Chronicles | Industry; Podcasts | Drug Regulatory Process; Drug Development |
| FDA's Biomarker Qualification Program | Industry; Videos | Biomarker; Drug Development |
| Biosimillars Patient and Prescriber Outreach Materials | Health Care Professional; Videos | Biosimilars; Drug Regulatory Process; Drug Development |
| FDA Drug Info Rounds | Health Care Professional; Videos | Drug Safety; MedWatch; IND; Drug Development; Drug Regulatory Process; Prescription Drug Promotion; Disease States; Registration and Listing; Generic Drugs |
| GDUFA II Videos and Resources | Industry; Videos | Drug Development; Generic Drugs |
| Regulatory Science at CDER Videos | Industry; Videos | Drug Regulatory Process; Drug Development |
| Biosimlars Online Courses, Webinars, and Presentations | Health Care Professional; Industry; Webinars | Biosimliars; Drug Regulatory Process; Drug Development |
| CDER Small Business and Industry Assistance (SBIA) Learn | Health Care Professional; Industry; Webinars | Drug Regulatory Process; Drug Development; Generic Drugs; OTC Drug Regulations; Registration and Listing; Electronic Submissions; Biosimilars; Drug Safety; IND |
| CDER Webinars | Health Care Professional; Industry; Webinars | Drug Regulatory Process; Drug Development; Generic Drugs; OTC Drug Regulations; Registration and Listing; Electronic Submissions; Biosimilars; Drug Safety; MedWatch; IND; Disease States; Prescription Drug Promotion; Cancer Drugs |
| Division of Drug Information Webinars | Health Care Professional; Webinars; CE Eligible | Drug Regulatory Process; Drug Development; Generic Drugs; OTC Drug Regulations; Biosimilars; Drug Safety; MedWatch; IND; Disease States; Prescription Drug Promotion; Cancer Drugs |
| Compounding Quality Center of Excellence On-Demand Training | Health Care Professional; Industry; Webinars; CE Eligible | Compounding; Drug Regulatory Process; Generic Drugs |
Resources for You
- FDA Continuing Education Programs
- Training and Continuing Education
- For questions contact CDER Division of Drug Information
Sub-Topic Paragraphs
Paragraph Header
Contact Us
Paragraph Header
Contact Us
Contact Point
Office of Communications
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993
Toll Free
(855) 543-3784
(301) 796-3400
Hours Available
CDER Division of Drug Information
For Updates on Twitter follow
Contact Point Twitter
@FDA_Drug_Info
Your source for the latest drug information.
Know the moment it happens.